[go: up one dir, main page]

MX2008000064A - Metodos y composiciones para el tratamiento de condiciones oftalmicas via retinol de suero, proteina de enlace de retinol de suero (rbp) y/o modulacion de retinol-rbp del suero. - Google Patents

Metodos y composiciones para el tratamiento de condiciones oftalmicas via retinol de suero, proteina de enlace de retinol de suero (rbp) y/o modulacion de retinol-rbp del suero.

Info

Publication number
MX2008000064A
MX2008000064A MX2008000064A MX2008000064A MX2008000064A MX 2008000064 A MX2008000064 A MX 2008000064A MX 2008000064 A MX2008000064 A MX 2008000064A MX 2008000064 A MX2008000064 A MX 2008000064A MX 2008000064 A MX2008000064 A MX 2008000064A
Authority
MX
Mexico
Prior art keywords
serum retinol
rbp
compositions
serum
ophthalmic conditions
Prior art date
Application number
MX2008000064A
Other languages
English (en)
Inventor
Jay Lichter
Nathan L Mata
Ken Widder
Original Assignee
Sirion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sirion Therapeutics Inc filed Critical Sirion Therapeutics Inc
Publication of MX2008000064A publication Critical patent/MX2008000064A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knock-out vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0306—Animal model for genetic diseases
    • A01K2267/0318—Animal model for neurodegenerative disease, e.g. non- Alzheimer's

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)

Abstract

Se describen compuestos que reducen los niveles de retinol en el suero, RBP en el suero y/o retinol-RBP en el suero que pueden ser usados para tratar condiciones oftalmicas asociadas con la sobreproduccion de productos de desperdicio que se acumulan durante el curso del ciclo visual. Se describen metodos y composiciones que usan tales compuestos y sus derivados para tratar por ejemplo las degeneraciones maculares y distrofias o para aliviar sintomas asociados con tales condiciones oftalmicas. Tales compuestos y sus derivados pueden ser usados como terapia de un solo agente o en combinacion con otros agentes o terapias.
MX2008000064A 2005-07-11 2006-07-10 Metodos y composiciones para el tratamiento de condiciones oftalmicas via retinol de suero, proteina de enlace de retinol de suero (rbp) y/o modulacion de retinol-rbp del suero. MX2008000064A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69851205P 2005-07-11 2005-07-11
PCT/US2006/026770 WO2007008821A2 (en) 2005-07-11 2006-07-10 Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (rbp), and/or serum retinol-rbp modulation

Publications (1)

Publication Number Publication Date
MX2008000064A true MX2008000064A (es) 2008-04-07

Family

ID=36955418

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008000064A MX2008000064A (es) 2005-07-11 2006-07-10 Metodos y composiciones para el tratamiento de condiciones oftalmicas via retinol de suero, proteina de enlace de retinol de suero (rbp) y/o modulacion de retinol-rbp del suero.

Country Status (18)

Country Link
US (2) US20070015827A1 (es)
EP (1) EP1904043A4 (es)
JP (1) JP2009500455A (es)
KR (1) KR20080055790A (es)
CN (1) CN101252924B (es)
AR (1) AR055075A1 (es)
AU (1) AU2006268374A1 (es)
BR (1) BRPI0612405A2 (es)
CA (1) CA2614627C (es)
EA (1) EA200800291A1 (es)
GB (1) GB2428975B (es)
IL (1) IL188528A0 (es)
MX (1) MX2008000064A (es)
NO (1) NO20080718L (es)
TW (1) TW200727894A (es)
UA (1) UA81382C2 (es)
WO (1) WO2007008821A2 (es)
ZA (1) ZA200800844B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2569691C (en) * 2004-06-23 2010-08-17 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
WO2006052860A2 (en) * 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
AU2005314039B2 (en) * 2004-12-08 2008-01-31 Revision Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases
US8877809B2 (en) 2007-09-12 2014-11-04 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating macular degeneration
CN101229147B (zh) * 2007-12-24 2010-09-01 复旦大学 N-4-羟苯视黄酰胺在制备抗肝纤维化药物中的用途
US20110210074A1 (en) * 2008-06-26 2011-09-01 Winchester James F Removal of myoglobin from blood and/or physiological fluids
JP5951625B2 (ja) * 2010-11-24 2016-07-13 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨークＴｈｅ Ｔｒｕｓｔｅｅｓ Ｏｆ Ｃｏｌｕｍｂｉａ Ｕｎｉｖｅｒｓｉｔｙ Ｉｎ Ｔｈｅ Ｃｉｔｙ Ｏｆ Ｎｅｗ Ｙｏｒｋ 加齢性黄斑変性症およびシュタルガルト病の処置のための非レチノイドｒｂｐ４アンタゴニスト
EP2648711A2 (en) * 2010-12-06 2013-10-16 ReVision Therapeutics, Inc. Compositions and methods for treating ophthalmic conditions
US9333202B2 (en) 2012-05-01 2016-05-10 The Trustees Of Columbia University In The City Of New York Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease
WO2013166041A1 (en) * 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US9938291B2 (en) 2013-03-14 2018-04-10 The Trustess Of Columbia University In The City Of New York N-alkyl-2-phenoxyethanamines, their preparation and use
US10092393B2 (en) 2013-03-14 2018-10-09 Allotex, Inc. Corneal implant systems and methods
WO2014151936A1 (en) 2013-03-14 2014-09-25 The Trustees Of Columbia University In The City Of New York Octahydropyrrolopyrroles, their preparation and use
ES2705247T3 (es) 2013-03-14 2019-03-22 Univ Columbia 4-fenilpiperidinas, su preparación y uso
EP2968303B1 (en) 2013-03-14 2018-07-04 The Trustees of Columbia University in the City of New York Octahydrocyclopentapyrroles, their preparation and use
EP3855181B1 (en) 2014-02-13 2024-11-06 Katairo GmbH Compounds for the treatment of lipofuscin related diseases
AU2015253232B2 (en) 2014-04-30 2020-10-01 The Trustees Of Columbia University In The City Of New York Substituted 4-phenylpiperidines, their preparation and use
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
EP3408285B1 (en) * 2016-01-25 2024-03-06 Universität Bern Nanospheres of sec14-like proteins and cognate ligands
GB201706009D0 (en) * 2017-04-13 2017-05-31 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of stargardt disease

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2004A (en) * 1841-03-12 Improvement in the manner of constructing and propelling steam-vessels
US4190594A (en) * 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4323581A (en) * 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
US4665098A (en) * 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4874795A (en) * 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4743400A (en) * 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
US5814612A (en) * 1991-04-09 1998-09-29 Sloan-Kettering Institute For Cancer Research Retinol derivatives and uses thereof
US6992108B1 (en) * 1991-12-18 2006-01-31 The Salk Institute For Biological Studies Means for the modulation of processes mediated by retinoid receptors and compounds useful therefor
US6093706A (en) * 1992-03-04 2000-07-25 Bioresponse, L.L.C. Combined dehydroepiandrosterone and retinoid therapy for epithelial disorders
US5314909A (en) * 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
US5399757A (en) * 1993-07-20 1995-03-21 Ortho Pharmaceutical Corporation Process for the preparation of N-(4-hydroxyphenyl)-retinamide
US5427571A (en) * 1994-08-08 1995-06-27 Cor-A-Vent Incorporated Ventilated cap system for the ridge of a roof
US5824685A (en) * 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5596011A (en) * 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
US5846220A (en) * 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US6034211A (en) * 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
US5955305A (en) * 1997-04-28 1999-09-21 Incyte Pharmaceuticals, Inc. Human retinoid binding protein
US5776915A (en) * 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
UA70925C2 (uk) * 1997-08-15 2004-11-15 Дюк Юнівесіті Спосіб лікування естрогенстимульованого раку
WO1999058126A1 (en) * 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
WO2000037750A2 (en) * 1998-12-17 2000-06-29 Diversi-Plast Products, Inc. Ridge cap vent
US6128870A (en) * 1999-05-24 2000-10-10 Kohler; Raymond L. Roof vent system
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
US6450882B1 (en) * 2000-08-30 2002-09-17 Liberty Diversified Industries, Inc. Precipitation resistant ridge vent
US20020031539A1 (en) * 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
WO2002032413A2 (en) * 2000-10-17 2002-04-25 Board Of Regents, The University Of Texas System A method to incorporate n-(4-hydroxyphenyl) retinamide in liposomes
JP4384409B2 (ja) * 2000-12-05 2009-12-16 チルドレンズ・ホスピタル・ロス・アンジエルス バイオアベイラビリティが増加したフェンレチニドの医薬組成物、およびその使用方法
US20030032078A1 (en) * 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
AU2002345563A1 (en) * 2001-06-15 2003-01-02 The Cleveland Clinic Foundation Radiometric quantitation of elicited eye autofluorescence
CA2450562A1 (en) * 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003003987A2 (en) * 2001-07-06 2003-01-16 The Ohio State University Research Foundation Solid phase synthesis of arylretinamides
WO2003007944A1 (en) * 2001-07-20 2003-01-30 Qlt, Inc. Treatment of macular edema with photodynamic therapy
AU2003301813A1 (en) * 2002-10-30 2004-06-07 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
US7354574B2 (en) * 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
US7566808B2 (en) * 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
KR20060135819A (ko) * 2004-02-17 2006-12-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 황반변성을 포함하는 안과질환의 관리
CA2569691C (en) * 2004-06-23 2010-08-17 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions with retinyl derivatives
WO2006033734A2 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006052860A2 (en) * 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
AU2005314039B2 (en) * 2004-12-08 2008-01-31 Revision Therapeutics, Inc. Methods, assays and compositions for treating retinol-related diseases

Also Published As

Publication number Publication date
WO2007008821A3 (en) 2007-07-12
CN101252924A (zh) 2008-08-27
AU2006268374A8 (en) 2008-03-20
EA200800291A1 (ru) 2008-06-30
CA2614627C (en) 2013-11-19
KR20080055790A (ko) 2008-06-19
AR055075A1 (es) 2007-08-01
US20070015827A1 (en) 2007-01-18
GB2428975B (en) 2008-08-13
CN101252924B (zh) 2013-06-19
CA2614627A1 (en) 2007-01-18
BRPI0612405A2 (pt) 2012-04-24
AU2006268374A1 (en) 2007-01-18
HK1122744A1 (en) 2009-05-29
ZA200800844B (en) 2009-04-29
JP2009500455A (ja) 2009-01-08
WO2007008821A2 (en) 2007-01-18
US20120288568A1 (en) 2012-11-15
UA81382C2 (en) 2007-12-25
GB0613730D0 (en) 2006-08-23
EP1904043A2 (en) 2008-04-02
TW200727894A (en) 2007-08-01
NO20080718L (no) 2008-04-02
EP1904043A4 (en) 2008-09-17
GB2428975A (en) 2007-02-14
IL188528A0 (en) 2008-04-13
AU2006268374A2 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
TW200727894A (en) Methods and compositions for treating ophthalmic conditions via serum retinol, serum retinol binding protein (RBP), and/or serum retinol-RBP modulation
TW200612891A (en) Methods and compositions for treating ophthalmic conditions with retinyl derivatives
WO2009042444A3 (en) Methods and compounds for treating retinol-related diseases
IN2012DN00352A (es)
MXPA05011886A (es) Metodos y composiciones para la prevencion y tratamiento de septicemia.
IL219721A (en) Load reconstituted lipoprotein complex for use in the method of treating dyslipidemia, Load reconstituted lipoprotein complex containing apolipoprotein and lipid segment, and a pharmacist's preparation containing them
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
IL208566A0 (en) Cd-37 specific binding molecule, compositions comprising the same and uses thereof
WO2006113242A3 (en) Method of increasing testosterone and related steroid concentrations in women
BRPI0415699A (pt) uso de oligossacarìdeo ácido e de oligossacarìdeo neutro, e, composições alimentìcia e lìquida
SG166813A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
CY1109985T1 (el) Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων
WO2006033734A3 (en) Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
TW200745124A (en) Azepinoindole derivatives as pharmaceutical agents
SG165387A1 (en) 5-lipoxygenase-activating protein (flap) inhibitors
AU2010266004A8 (en) Method of treating cancer with Dll4 antagonist and chemotherapeutic agent
GB2442915B (en) Perylenequinone derivatives and uses thereof
WO2008029169A3 (en) Method of treating respiratory disorders
WO2007075439A3 (en) Compositions and methods for treating obesity and related metabolic disorders
WO2008013984A3 (en) Compositions and methods for treating or preventing ophthalmic disease
TN2009000213A1 (en) Combination
WO2008127654A3 (en) Methods and compositions for intra-articular coagulation proteins
WO2009114729A3 (en) Compounds, compositions and methods for treating lysosomal storage diseases and disorders
UA99434C2 (ru) Применение производных алкилфосфолипидов со сниженной цитотоксичностью
WO2009009034A3 (en) Methods and compositions useful in the treatment of mucositis

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: REVISION THERAPEUTICS, INC.

FA Abandonment or withdrawal